Zydus Lifesciences Limited Share Price & Analysis

Zydus Lifesciences receives credit rating update

*Zydus Lifesciences receives credit rating update.* The company's latest credit rating has been disclosed in a regulatory filing. No changes in financial outlook or rating grade were specified. The update is routine and reflects ongoing credit monitoring. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CreditRating

Zydus Lifesciences reports Q1FY26 financial results

*Zydus Lifesciences reports Q1FY26 financial results*. The company has submitted its financial results for the quarter ended June 30, 2026. Key metrics include revenue of **₹2,147 crore** and net profit of **₹237 crore**, showing growth year-on-year. Results reflect strong performance in both domestic and international markets. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Zydus, Lupin face FDA flag on weight-loss injectable exports

*Zydus, Lupin face FDA flag on weight-loss injectable exports* — The U.S. FDA issued a warning letter over quality issues in weight-loss injectables exported by Indian firms Zydus and Lupin. This may disrupt shipments and trigger regulatory scrutiny. Shares may face near-term pressure as compliance costs or plant upgrades loom. **No patient harm reported**, but export delays could impact revenue. 📊 *STOCKS:* ZYDUSLIFE, LUPIN | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA

Zydus wins USFDA approval for hormone patch with 180-day exclusivity

*Zydus wins USFDA approval for hormone patch with 180-day exclusivity* — Zydus Lifesciences has received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, a hormone replacement therapy. The product is eligible for **180-day competitive generic therapy (CGT) exclusivity**, offering a market edge. This approval expands Zydus’s presence in the U.S. generics segment and could boost near-term revenues. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Zydus to set up pharma plant in Sri Lanka

*Zydus to set up pharma plant in Sri Lanka* — Zydus Lifesciences announced a pact with Sri Lanka’s Board of Investment to build a manufacturing facility. The move marks a strategic international expansion for the company. Financial details and capacity estimates were not disclosed. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Expansion

Zydus' Keytruda biosimilar accepted for USFDA review

*Zydus' Keytruda biosimilar accepted for USFDA review*. Zydus Lifesciences announced that FYB206, its biosimilar to Keytruda®, has been accepted for review by the USFDA. This marks the first publicly announced Keytruda biosimilar to reach this stage. The move positions Zydus for potential market entry in the high-value oncology segment. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma

Zydus reports positive Phase II(b) trial results for Saroglitazar Mg

*Zydus reports positive Phase II(b) trial results for Saroglitazar Mg*. Zydus Lifesciences announced positive topline results from its EVIDENCES-X Phase II(b) trial for Saroglitazar Mg in MASH patients. The drug showed **improvement in liver histology** and metabolic parameters, boosting near-term pipeline hopes. This success enhances regulatory prospects and may drive investor sentiment positively. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ClinicalTrial

Zydus wins USFDA approval for Ascorbic Acid Injection

*Zydus wins USFDA approval for Ascorbic Acid Injection*. The company announced final approval for its injectable vitamin C product with **180-day CGT exclusivity**, boosting its US generics portfolio. This exclusivity may delay rival approvals, enhancing near-term revenue potential. The development strengthens Zydus’s position in the competitive USFDA-regulated market. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Zydus launches India's first once-daily nebulised LAMA for COPD

*Zydus launches India's first once-daily nebulised LAMA for COPD*. The company introduced REVAHALE, a novel treatment for chronic obstructive pulmonary disease (COPD), marking a significant product launch in the respiratory therapeutics space. This positions Zydus as a pioneer in nebuliser-based maintenance therapy in India. The launch could drive future revenue growth and market share gains. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma

Zydus gets USFDA nod for injectable drug with 180-day exclusivity

*Zydus gets USFDA nod for injectable drug with 180-day exclusivity*. Zydus Lifesciences announced final approval from the USFDA for Indocyanine Green for Injection, granting it **180-day** Competitive Generic Therapy (CGT) exclusivity. This approval allows Zydus to launch the product ahead of competitors, potentially capturing early market share. The exclusivity period is expected to provide a revenue boost in the near term. 📊 *STOCKS:* $ZYDUSLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA